Health & bio
Nuvation Bio's IBTROZI sNDA Filed with FDA on May 6
Supplemental NDA for IBTROZI, for ROS1-positive advanced non-small cell lung cancer, submitted to FDA.
Primary sources · 1
Supplemental NDA for IBTROZI, for ROS1-positive advanced non-small cell lung cancer, submitted to FDA.
7 must-reads · 17 fields · tracked storylines delivered to your inbox daily. Pick only the fields you want; unsubscribe anytime.